CD36 overexpression in ritonavir-treated THP-1 cells is reversed by α-tocopherol

Free Radical Biology and Medicine

Volumn 38, Issue 8, 2005, Pages 1047-1056

  Munteanu, Adelina ^a   Zingg, Jean Marc ^a   Ricciarelli, Roberta ^b   Azzi, Angelo ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Atherosclerosis; Endocytosis; Free radicals; Lipoproteins; Proteasome; Ritonavir; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ESTER; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEASOME; RITONAVIR;

ARTICLE; CELL LEVEL; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 15244358438     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.12.030     Document Type: Article

References (48)

1. J. Dressman, J. Kincer, S.V. Matveev, L. Guo, R.N. Greenberg, T. Guerin, D. Meade, X.A. Li, W. Zhu, A. Uittenbogaard, M.E. Wilson, and E.J. Smart HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages J. Clin. Invest. 111 2003 389 397
2. D. Periard, A. Telenti, P. Sudre, J.J. Cheseaux, P. Halfon, M.J. Reymond, S.M. Marcovina, M.P. Glauser, P. Nicod, R. Darioli, and V. Mooser Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study Circulation 100 1999 700 705
3. A. Nakata, Y. Nakagawa, M. Nishida, S. Nozaki, J. Miyagawa, T. Nakagawa, R. Tamura, K. Matsumoto, K. Kameda-Takemura, S. Yamashita, and Y. Matsuzawa CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta Arterioscler. Thromb. Vasc. Biol. 19 1999 1333 1339
4. U.P. Steinbrecher Receptors for oxidized low density lipoprotein Biochim. Biophys. Acta 1436 1999 279 298
5. E.A. Podrez, M. Febbraio, N. Sheibani, D. Schmitt, R.L. Silverstein, D.P. Hajjar, P.A. Cohen, W.A. Frazier, H.F. Hoff, and S.L. Hazen Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species J. Clin. Invest. 105 2000 1095 1108
6. M. Febbraio, N.A. Abumrad, D.P. Hajjar, K. Sharma, W. Cheng, S.F. Pearce, and R.L. Silverstein A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism J. Biol. Chem. 274 1999 19055 19062
7. D.P. Hajjar, and M.E. Haberland Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs J. Biol. Chem. 272 1997 22975 22978
8. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 1998 229 240
9. J. Han, D.P. Hajjar, M. Febbraio, and A.C. Nicholson Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor CD36 J. Biol. Chem. 272 1997 21654 21659
10. T.M. Riddle, D.G. Kuhel, L.A. Woollett, C.J. Fichtenbaum, and D.Y. Hui HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus J. Biol. Chem. 276 2001 37514 37519
11. J.B. Kim, H.M. Wright, M. Wright, and B.M. Spiegelman ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand Proc. Natl. Acad. Sci. USA 95 1998 4333 4337
12. A.T. Nguyen, A. Gagnon, J.B. Angel, and A. Sorisky Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis AIDS 14 2000 2467 2473
13. D.Y. Hui HIV protease inhibitors and atherosclerosis J. Clin. Invest. 111 2003 317 318
14. R. Ricciarelli, J.M. Zingg, and A. Azzi Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured human aortic smooth muscle cells Circulation 102 2000 82 87
15. G.W. Burton, M.G. Traber, R.V. Acuff, D.N. Walters, H. Kayden, L. Hughes, and K.U. Ingold Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E Am. J. Clin. Nutr. 67 1998 669 684
16. T.L. Innerarity, R.E. Pitas, and R.W. Mahley Methods in Enzymology vol. 129 1986 Academic Press San Diego 542 848
17. M. Goppelt, and K. Resch Densitometric quantitation of individual phospholipids from natural sources separated by one-dimensional thin-layer chromatography Anal. Biochem. 140 1984 152 156
18. J.I. Ruiz, and B. Ochoa Quantification in the subnanomolar range of phospholipids and neutral lipids by monodimensional thin-layer chromatography and image analysis J. Lipid Res. 38 1997 1482 1489
19. K.J. Rodgers, and R.T. Dean Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates Int. J. Biochem. Cell Biol. 35 2003 716 727
20. Y. Zeng, N. Tao, K.N. Chung, J.E. Heuser, and D.M. Lublin Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1 J. Biol. Chem. 278 2003 45931 45936
21. T. Ravid, R. Doolman, R. Avner, D. Harats, and J. Roitelman The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase J. Biol. Chem. 275 2000 35840 35847
22. P. Andre, M. Groettrup, P. Klenerman, R. de Giuli, B.L. Booth Jr., V. Cerundolo, M. Bonneville, F. Jotereau, R.M. Zinkernagel, and V. Lotteau An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses Proc. Natl. Acad. Sci. USA 95 1998 13120 13124
23. M. Groettrup, and G. Schmidtke Selective proteasome inhibitors: modulators of antigen presentation? Drug Discovery Today 4 1999 63 71
24. N. Laurent, S. de Bouard, J.S. Guillamo, C. Christov, R. Zini, H. Jouault, P. Andre, V. Lotteau, and M. Peschanski Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo Mol. Cancer Ther. 3 2004 129 136
25. D.L. Silver, and A.R. Tall The cellular biology of scavenger receptor class B type I Curr. Opin. Lipidol. 12 2001 497 504
26. D.L. Silver, N. Wang, and S. Vogel Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels J. Biol. Chem. 278 2003 28528 28532
27. C.K. Glass, and J.L. Witztum Atherosclerosis: the road ahead Cell 104 2001 503 516
28. J.M. Zingg, R. Ricciarelli, and A. Azzi Scavenger receptor regulation and atherosclerosis Biofactors 11 2000 189 200
29. M.J. Sampson, I.R. Davies, S. Braschi, K. Ivory, and D.A. Hughes Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes Atherosclerosis 167 2003 129 134
30. M. Takaku, Y. Wada, K. Jinnouchi, M. Takeya, K. Takahashi, H. Usuda, M. Naito, H. Kurihara, Y. Yazaki, Y. Kumazawa, Y. Okimoto, M. Umetani, N. Noguchi, E. Niki, T. Hamakubo, and T. Kodama An in vitro coculture model of transmigrant monocytes and foam cell formation Arterioscler. Thromb. Vasc. Biol. 19 1999 2330 2339
31. L. Hicke Getting' down with ubiquitin: turning off cell-surface receptors, transporters and channels Trends Cell Biol. 9 1999 107 112
32. G.J. Strous, and R. Govers The ubiquitin-proteasome system and endocytosis J. Cell Sci. 112 Pt. 10 1999 1417 1423
33. L. Hicke Protein regulation by monoubiquitin Nat. Rev. Mol. Cell Biol. 2 2001 195 201
34. G. Schmidtke, S. Emch, M. Groettrup, and H.G. Holzhutter Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome J. Biol. Chem. 275 2000 22056 22063
35. G. Schmidtke, H.G. Holzhutter, M. Bogyo, N. Kairies, M. Groll, R. de Giuli, S. Emch, and M. Groettrup How an inhibitor of the HIV-I protease modulates proteasome activity J. Biol. Chem. 274 1999 35734 35740
36. P. van Kerkhof, C.M. Alves dos Santos, M. Sachse, J. Klumperman, G. Bu, and G.J. Strous Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins Mol. Biol. Cell 12 2001 2556 2566
37. K.J. Davies Degradation of oxidized proteins by the 20S proteasome Biochimie 83 2001 301 310
38. T. Grune, K. Merker, G. Sandig, and K.J. Davies Selective degradation of oxidatively modified protein substrates by the proteasome Biochem. Biophys. Res. Commun. 305 2003 709 718
39. R. Shringarpure, T. Grune, and K.J. Davies Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells Cell. Mol. Life Sci. 58 2001 1442 1450
40. 2 J. Exp. Med. 188 1998 2257 2265
41. B. Dahlmann, B. Becher, A. Sobek, C. Ehlers, F. Kopp, and L. Kuehn In vitro activation of the 20S proteasome Enzyme Protein 47 1993 274 284
42. I. Ruiz de Mena, E. Mahillo, J. Arribas, and J.G. Castano Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase Biochem. J. 296 Pt. 1 1993 93 97
43. P. Arizti, J. Arribas, and J.G. Castano Modulation of the multicatalytic proteinase complex by lipids, interconversion and proteolytic processing Enzyme Protein 47 1993 285 295
44. J. Arribas, and J.G. Castano Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver J. Biol. Chem. 265 1990 13969 13973
45. T. Reinheckel, N. Sitte, O. Ullrich, U. Kuckelkorn, K.J. Davies, and T. Grune Comparative resistance of the 20S and 26S proteasome to oxidative stress Biochem. J. 335 Pt. 3 1998 637 642
46. B.S. Conklin, W. Fu, P.H. Lin, A.B. Lumsden, Q. Yao, and C. Chen HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries Cardiovasc. Res. 63 2004 168 175
47. O. Cachia, J.E. Benna, E. Pedruzzi, B. Descomps, M.A. Gougerot-Pocidalo, and C.L. Leger Alpha-tocopherol inhibits the respiratory burst in human monocytes: attenuation of p47(phox) membrane translocation and phosphorylation J. Biol. Chem. 273 1998 32801 32805
48. H.Y. Huh, S.F. Pearce, L.M. Yesner, J.L. Schindler, and R.L. Silverstein Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation Blood 87 1996 2020 2028